More MS news articles for May 2004

Nastech Presents Scientific Abstracts at AAPS National Biotechnology Conference

Development and Phase I Clinical Testing of an Intranasal Formulation of Interferon-beta-1a

Extracted from:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/05-19-2004/0002177616&EDATE=

May 19, 2004
Source: Nastech Pharmaceutical Company Inc.
Henry R. Costantino and Gordon Brandt
PRNewswire

Nastech has developed and tested an intranasal formulation of interferon-beta-1a suitable for initial human clinical testing for the treatment of multiple sclerosis. An in vitro screening method was successfully employed to identity a candidate intranasal formulation of interferon-beta-1a. An early human clinical study suggested that there was about 20-25 percent bioavailability for this formulation. Ongoing work has identified an improved formulation.